Ajanta Pharma

Ajanta Pharma Limited
Company type
Public
Industry
Founded1973 (1973)
Headquarters
Mumbai, Maharashtra[1]
,
India
Key people
  • Yogesh Agrawal (Managing Director)
  • Rajesh Agrawal (Joint Managing Director)
ProductsBranded Generic Formulations / Medicines
RevenueIncrease ₹4,648 crore (US$490 million) (2025)
Increase ₹1,260 crore (US$130 million) (2025)
Increase ₹920 crore (US$97 million) (2025)
Number of employees
9,628 (March 2025)
Subsidiaries
  • Ajanta Pharma Philippines Inc.
  • Ajanta Pharma USA Inc.[2]
  • Ajanta Pharma Nigeria Ltd.[3]
Websitewww.ajantapharma.com
Footnotes / references
Financials as of 31 March 2025.[4]

Ajanta Pharma Limited (APL) is an Indian multinational pharmaceutical company. The company operates in India, the United States, and over 30 countries across Africa, Southeast Asia, West Asia, and the CIS. It was established in 1973..[1][2][3]

Markets and business

Ajanta Pharma has over 1,400 products registered currently in various countries and an equal number of products are under approval. In India, the company is a branded generic company focused on a few high growth specialty therapies in ophthalmology, dermatology, cardiology, and pain management.

Ajanta Pharma exports products to over 30 countries in Asia and Africa. In these markets, the company serves a wide range of therapeutic products in the areas of antimalarial, cardiovascular, gastrointestinal, antibiotic, dermatology, antihistamine, multivitamin, gynecology, and pain management.

Ajanta Pharma has recently stepped up its presence in the United States with a select product portfolio, which includes niche and complex technology products. Currently, the company has 27 products in the US market.[5]

History

In the early 2000s, Ajanta Pharma was identified as a significant contributor to foreign exchange earnings, alongside Reddy Labs, primarily through sales in Southeast Asia.[6] In 2003, a joint venture between Ajanta Pharma and the Ministry of Health in Turkmenistan supplied approximately half of the country’s pharmaceutical requirements.[6] The company also entered into joint ventures with regional governments in countries including Uzbekistan, Kazakhstan, Kyrygyzstan, and Tajikistan. These ventures were discontinued in the 2010s due to lack of profitability.[7]

The company reported a significant loss in 2005[nt 1] due to a decline in the value of its investments, which was reported to be four times its annual profit for that year.[8] In the same year, Ajanta Pharma recorded sales of ₹13.56 billion, which was reported as the highest among Indian pharmaceutical companies at the time.[9]

In 2015, the company’s stock performance over the preceding four years was noted for significant appreciation, and its inclusion in the BSE 500 index was reported.[10] By 2019, the company was listed on the S&P BSE 200 index.[11]

Manufacturing facilities

Ajanta Pharma operates seven manufacturing facilities in India. Six facilities manufacture finished formulations, including Dahej and Paithan plants which is approved by the US FDA and Guwahati plant which caters to domestic and emerging markets. Another plant manufactures active pharmaceutical ingredients (APIs) primarily for captive consumption.

Bayer[nt 2] filed suit before the Delhi High Court accusing Ajanta of patent infringement on the erectile dysfunction treatments vardenafil and vardenafil hydrochloride.[12] Ajanta argued that Bayer was not using its patent in India for the benefit of India, which led the court to provide partial relief to an injunction granted to Bayer, allowing Ajanta to manufacture but not sell the product, in January 2017.[12] Bayer and Ajanta reached an unspecified agreement after mediation was ordered by the court in February 2017.[12]

References

  1. ^ a b "Welcome To Ajanta Pharma". Ajantapharma.com. Retrieved 29 February 2016.
  2. ^ a b "Stock Snippets". Daily Market Insights. TriFid Research. 15 June 2016. p. 2 – via Internet Archive. Ajanta Pharma announced the launch of anti-dementia Memantine Hydrochloride tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc.
  3. ^ a b "Ajanta Pharma Limited - Our Business". Company. Retrieved 29 February 2016.
  4. ^ "Annual Report 2024-25" (PDF). Ajanta Pharma. Retrieved 11 July 2025.
  5. ^ "Profit After Tax at 14% of Revenue (3rd Quarter & 9 Months, FY 2019 Consolidated Results)" (PDF) (Press release). Ajanta Pharma Limited. Archived from the original (PDF) on 27 September 2020.
  6. ^ a b Lal, Rollie (2006). Central Asia and Its Asian Neighbors: Security and Commerce at the Crossroads. United States: Project Air Force (Rand). pp. 32–3. ISBN 0-8330-3878-8 – via Google Books (Preview).
  7. ^ GOI Considering Russian Thrust in Central Asia (Partial extract from original diplomatic, classified cable). United States Department of State. 26 September 2015. p. 2. Retrieved 8 December 2019 – via Internet Archive.
  8. ^ "Investments". Accounting & Analysis: The Indian Experience (Professional ed.). Global Data Services of India (CRISIL). 2006. p. 153. ISBN 9788190342704 – via Google Books (Preview).
  9. ^ Thukral, R. K., ed. (2016). India Top 10 Year Book 2016. New Delhi, India: Publication Cell (Datanet India). p. 85. ISBN 978-93-80590-60-8 – via Google Books (Preview).
  10. ^ Oberoi, Rahul (April 2015). "Bullish Moves: We discuss three ratios that can help identify good stocks". Money Today. Vol. 10, no. 4. New Delhi, India: India Today Group. p. 49 – via Internet Archive.
  11. ^ "Ajanta Pharma Ltd Live Stock Price, Ajantpharm Live Share Price". BSE. 8 December 2019. Retrieved 8 December 2019.{{cite web}}: CS1 maint: url-status (link)
  12. ^ a b c Kleyn, Madelein; van Wyk, Louis, eds. (2019). International Pharmaceutical Law and Practice. LexisNexis. pp. §14.09[11]. ISBN 9781579114725 – via Google Books (Preview).

Notes

  1. ^ Year ending 31 March 2005
  2. ^ Specifically Bayer Intellectual Property GMBH

Patent applications in India

Products subject to price control in India

This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.